Home/Filings/4/0001415889-24-021057
4//SEC Filing

Winningham Rick E 4

Accession 0001415889-24-021057

CIK 0001583107other

Filed

Aug 8, 8:00 PM ET

Accepted

Aug 9, 6:05 PM ET

Size

6.5 KB

Accession

0001415889-24-021057

Insider Transaction Report

Form 4
Period: 2024-08-07
Winningham Rick E
DirectorChief Executive Officer
Transactions
  • Award

    Ordinary Shares

    2024-08-07$7.83/sh+3,252$25,4631,839,896 total
Holdings
  • Ordinary Shares

    (indirect: As Custodian)
    3,900
  • Ordinary Shares

    (indirect: By Trust)
    92,567
Footnotes (1)
  • [F1]Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on August 7, 2024. Transaction was with the Issuer and did not involve an open market transaction.

Issuer

Theravance Biopharma, Inc.

CIK 0001583107

Entity typeother

Related Parties

1
  • filerCIK 0001302443

Filing Metadata

Form type
4
Filed
Aug 8, 8:00 PM ET
Accepted
Aug 9, 6:05 PM ET
Size
6.5 KB